2022
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA
Remon J, Lacas B, Herbst R, Reck M, Garon EB, Scagliotti GV, Ramlau R, Hanna N, Vansteenkiste J, Yoh K, Groen HJM, Heymach JV, Mandrekar SJ, Okamoto I, Neal JW, Heist RS, Planchard D, Pignon JP, Besse B, group A, Besse B, Lacas B, Pignon J, Remon J, Berghmans T, Dahlberg S, Felip E, Berghmans T, Besse B, Dahlberg S, Felip E, Garon E, Groen H, Hanna N, Heist R, Herbst R, Heymach J, Lacas B, Adjei A, Heist R, Mandrekar S, Neal J, Okamoto I, Pignon J, Ramlau R, Remon J, Reck M, Scagliotti G, Vansteenkiste J, Yoh K. ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. European Journal Of Cancer 2022, 166: 112-125. PMID: 35286903, DOI: 10.1016/j.ejca.2022.02.002.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerProgression-free survivalAdvanced non-small cell lung cancerFirst-line therapyCell lung cancerIndividual patient dataHazard ratioYounger patientsLung cancerPulmonary thromboembolic eventsPatient dataSecond-line treatmentFirst-line treatmentRisk of hypertensionFixed-effects modelOS benefitPFS benefitThromboembolic eventsOverall survivalSubgroup analysisAntiangiogenicsMeta-AnalysisPatientsMedical needChemotherapy
2021
Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A).
Reckamp K, Redman M, Dragnev K, Villaruz L, Faller B, Al Baghdadi T, Hines S, Qian L, Minichiello K, Gandara D, Herbst R, Kelly K. Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A). Journal Of Clinical Oncology 2021, 39: 9075-9075. DOI: 10.1200/jco.2021.39.15_suppl.9075.Peer-Reviewed Original ResearchVascular endothelial growth factorThromboembolic eventsAdvanced non-small cell lung cancerNon-small cell lung cancerPlatinum-based doublet therapyPD-L1 inhibitor therapyGrade 5 AEsTreatment-related AEsVEGF receptor inhibitionGrade 3 toxicityAdverse event profilePD-L1 expressionAdverse event assessmentCell lung cancerDuration of responseTumor immune microenvironmentStandard of carePhase IIEndothelial growth factorMultiple tumor typesCare armCommon AEsECOG 0Checkpoint inhibitorsDoublet therapy
2006
Toxicities of Antiangiogenic Therapy in Non–Small-Cell Lung Cancer
Herbst RS. Toxicities of Antiangiogenic Therapy in Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2006, 8: s23-s30. PMID: 17239287, DOI: 10.3816/clc.2006.s.010.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBenzenesulfonatesBevacizumabCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellHumansIndolesLung NeoplasmsNiacinamidePhenylurea CompoundsPiperidinesPyridinesPyrrolesQuinazolinesSorafenibSunitinibVascular Endothelial Growth FactorsConceptsAnti-VEGF antibodyCell lung cancerVascular endothelial growth factorAntiangiogenic agentsOverall survivalLung cancerPhase III pivotal trialsClass-effect toxicitiesFirst-line chemotherapyAdverse event profileSquamous cell histologyChemotherapy-associated toxicityVEGFR tyrosine kinaseTyrosine kinase inhibitorsEndothelial growth factorMetastatic NSCLCThromboembolic eventsCell histologyPivotal trialsEvent profileRisk factorsVEGF receptor activityAntiangiogenic therapySmall molecule inhibitorsTumor types